Vitamin D and response to vaccination
Condition | Age/years old | Study | Results | Reference |
---|---|---|---|---|
Healthy, community-dwelling individuals | ≥ 65 | Influenza vaccination H1N1, H3N2, or B virus | Levels of Vitamin D were not correlated with seroprotection or seroconversion | [72] |
Healthy individuals | 50–74 | Influenza vaccination A/California/H1N1-like virus | Vitamin D levels at baseline correlated with day 28 hemagglutination inhibition assay | [73] |
Healthy individuals | 18–49 | 1 mg 1,25OH at the site adjacent to influenza vaccine | Hemagglutination inhibition assay (H1N1, H3N2, B virus) is not different in comparison with placebo | [82] |
Healthy individuals | 26–35 | 2,000 IU vitamin D/day for 9 weeks, vaccination tetanus/ diphtheria toxoid | Discrete higher IgG levels and no difference in specific IgA in comparison with placebo | [83] |
Splenectomised patients | ≥ 40 | Vaccinated against S. pneumoniae or Neisseria meningitides | Same levels of vitamin D at baseline, similar production of antibodies | [81] |
VB: Writing—original draft, Writing—review & editing.
The author declares that there are no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
The study was supported by CAPES PrInt UNIFESP [88881.310735/2018-01]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2023.